NCM Boston | Oxford Nanopore Technologies
NCM Boston
A
)
Andreas CzechBioNTech, Germany
)
Alex KneubehlBaylor College of Medicine, USA
)
Anne-Sophie LebreCHU Reims, France
)
Ailsa MacCalmanUniversity of Exeter, UK
)
Anastasia McKinlayIndiana University & HHMI, USA
)
Amit MathurSanofi, USA
)
Ana PeresThe University of North Carolina at Chapel Hill, USA
)
Aaron VinyColumbia University Irving Medical Center, USA
)
Akelia Wauchope-OdumboAssociate Director, Technical Applications — Americas, Oxford Nanopore Technologies
B
)
Bronya BoydonMachine Learning Bioinformatician, Oxford Nanopore Technologies
)
Bradley HallAsuragen, USA
)
Bryan LelandBioinformatics Manager, Commercial Applications, Oxford Nanopore Technologies
)
Benjamin C. ReinerUniversity of Pennsylvania, USA
)
Brynja SigurpálsdóttirdeCODE genetics, Iceland
C
)
Cory BernhardsDEVCOM Chemical Biological Center, USA
)
Chris BrownVP Strategic Programmes, Oxford Nanopore Technologies
)
Colette CôtéPathoQuest, USA
)
Christian GallardoSeattle Children's Research Institute, USA
)
Carol GreiderUniversity of California, Santa Cruz, USA
)
Chun-Chieh LinDartmouth Health, USA
)
Chad PollardWasatch BioLabs, USA
)
Charles A. SwoffordMIT Center for Biomedical Innovation, USA
)
Carly TyerApplications Scientist, Oxford Nanopore Technologies
)
Carika WeldonCariGenetics, Bermuda
D
)
Daniel K. FabianLonza, UK
)
Dan FordhamDirector, Strategic Product Management EMEA, Oxford Nanopore Technologies
)
Daniel KimUniversity of California, Santa Cruz, USA
)
Dmitrijs RotsErasmus MC, Netherlands
)
David VanHouteRegeneron Pharmaceuticals, USA
)
David YarmoshATCC, USA
)
)
G
)
Gabriela PozoUniversity of San Francisco de Quito, Ecuador
)
Gordon SangheraCEO, Oxford Nanopore Technologies
)
Gaston VondenhoffLonza, The Netherlands
H
)
Heather CarletonCenters for Disease Control & Prevention, USA
)
Helen GunterThe BASE Facility, The University of Queensland, Australia
J
)
Jessica AndersonSenior Field Applications Scientist, Oxford Nanopore Technologies
)
Justin BeckerDana-Farber Cancer Institute & Massachusetts General Hospital, USA
)
Jade BartoloAssociate Director, Automation, Oxford Nanopore Technologies
)
Jack ColicchioSound Agriculture, USA
)
Julie CollensVP, Commercial Operations AMR, Oxford Nanopore Technologies
)
Jimmy CreithField Applications Scientist, Bioinformatics, Oxford Nanopore Technologies
)
J. (Gus) GustafsonUniversity of Washington, USA
)
Julie HaendigesU.S. Food and Drug Administration, USA
K
)
Karine ChoquetUniversity of Sherbrooke, Canada
)
Keith ConnollyModalis Therapeutics, USA
)
Kamil KhanipovThe University of Texas Medical Branch, USA
)
Katherine LawrenceMachine Learning and Bioinformatics Manager, Oxford Nanopore Technologies
L
)
Lucia DaxingerLeiden University Medical Center, Netherlands
)
Lantana GrubVanderbilt University, USA
)
Lakmal JayasingheSenior VP, R&D Biologics, Oxford Nanopore Technologies
)
Laura KamenetzkyCONICET, Argentina
)
Logan MulroneyEMBL-EBI, UK & IIT, Italy
M
)
Matthew BainbridgeRady Children's Institute for Genomic Medicine, USA
)
Michael DeanNational Cancer Institute, USA
)
Mathilde FilserCurie Institute, France
)
Megan L. NoonanWashington University School of Medicine in St. Louis, USA
)
Matt ParkerDirector, Clinical Bioinformatics Software, Oxford Nanopore Technologies
)
Mile SikicGenome Institute of Singapore, A*STAR, Singapore
)
Mike VellaSenior Director, Machine Learning, Oxford Nanopore Technologies
)
)
P
)
Philipp ReschenederSenior Director, Applications Bioinformatics, Oxford Nanopore Technologies
)
Paula SaffieClinica Santa María, Chile
)
R
)
Ranjith AnandeGenesis, USA
)
Rachel O’NeillUniversity of Connecticut, USA
)
Rachel RubinsteinTechnical Product Manager, Software, Oxford Nanopore Technologies
)
Rosemary Sinclair DokosSenior VP, Product and Programme Management, Oxford Nanopore Technologies
)
Radhakrishna TirumalaiMerck & Co., USA
)
Rhydian WindsorResearch Scientist, Machine Learning, Oxford Nanopore Technologies
S
)
Stacy L. SpringsMIT Center for Biomedical Innovation, USA
)
Stephanie AbernathyVice President, Sales, Americas, Oxford Nanopore Technologies
)
Stephanie ChrysanthouMemorial Sloan Kettering Cancer Center, USA
)
Scott HickeyDirector, Commercial Applications, Oxford Nanopore Technologies
)
Shilpa KobrenHarvard Medical School, USA
)
Serge MonpoehoRegeneron Pharmaceuticals, USA
)
Svetlana MadjunkovaCReATe Fertility Centre, Canada
)
Sean McKenzieAssociate Director, Genomic Applications Bioinformatics, Oxford Nanopore Technologies
)
Samuel ShelburneThe University of Texas MD Anderson Cancer Center, USA
)
Sebastian B. TeitzveryTeitz Consulting, Germany
T
)
Thomas GarciaBaylor College of Medicine, USA
)
Tasos GogakosArena BioWorks & Massachusetts General Hospital, USA
)
Tim WalkerApplied Industrial Support Specialist, Oxford Nanopore Technologies
)
)
)
Oxford Nanopore Technologies
Stephanie Chrysanthou
)
- Job title
- Institution
- Memorial Sloan Kettering Cancer Center, USA
- Biography
Stephanie Chrysanthou leads the R&D team in the Integrated Genomics Operation facility at Memorial Sloan Kettering Cancer Center, USA. Her goal is to adopt and optimize new genomic technologies to enable basic, clinical and translational projects across the Cancer Center. One of her research interests includes optimizing nanopore sequencing methodologies for bulk and single-cell analysis to detect structural variants and transcript isoforms in cancer patient samples. Previously, during her doctoral and post-doctoral studies at the University of Cambridge, UK and Albert Einstein College of Medicine, New York, she worked on the epigenetic mechanisms of early mammalian embryonic development.